Mayo Clinic Multiple Myeloma SPORE

梅奥诊所多发性骨髓瘤孢子

• 批准号: 10706314
• 负责人: Peter Leif Bergsagel
• 金额: $ 197.64万
• 依托单位: MAYO CLINIC ARIZONA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10706314
• 关键词: Advocate; Area; Arizona; Basic Science; Benign; Bioinformatics; Biological Specimen database; Biology; Biometry; Bispecific Antibodies; Cancer Center; Cancer Research Project; Caring; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Complement; Comprehensive Cancer Center; Development; Early Diagnosis; Florida; Foundations; Functional disorder; Funding; Genetic; Goals; Immune response; Immunotherapy; Infrastructure; Institution; Integration Host Factors; International; Joints; Laboratories; Leadership; Malignant - descriptor; Minnesota; Multiple Myeloma; Ontario; Patients; Peer Review; Peer Review Grants; Phase I Clinical Trials; Prevention; Productivity; Prognosis; Publications; Regimen; Research; Research Personnel; Research Project Grants; Research Support; Resources; Risk; Site; Translating; Tumor Biology; Tumor Markers; Vesicular stomatitis Indiana virus; Virotherapy; Work; career; clinical database; clinical epidemiology; high risk; immunoregulation; improved; innovation; multiple omics; novel; oncolytic virotherapy; prognostic index; programs; sound; success; survivorship; translational cancer research; translational clinical trial; translational scientist; treatment optimization; tumor microenvironment; tumor-immune system interactions

PROJECT SUMMARY/ABSTRACT The Mayo Clinic Multiple Myeloma SPORE (SPORE) is a dynamic, productive, translational cancer research program based at all three Mayo Clinic sites (Rochester MN, Jacksonville FL, Phoenix AZ), now with input from the Princess Margaret Cancer Centre in Toronto, Ontario. From 2003-2013 we participated in the joint DFCI/Mayo Clinic Multiple Myeloma SPORE, and since 2015 in the Mayo Clinic Multiple Myeloma SPORE. At the center of the ongoing success of the SPORE is the collaborative interaction between investigators throughout the Mayo Foundation, as well as SPORE basic laboratory, translational and clinical investigators and patient advocates focused on MM. The overall goal of the SPORE is to support innovative, interactive, rigorous translational myeloma research that leverages the expertise of laboratory, translational and clinical expertise. Over the last funding period, the SPORE has been highly productive as demonstrated by identification of new tumor markers and prognostic indices that are being used clinically; scientific findings that led to innovative clinical trials both within and outside the SPORE; multiple publications with many authored by investigators from multiple sites; and brisk accrual to translational clinical trials. The SPORE was involved in multiple productive vertical and horizontal collaborations with other national and international academic institutions and organizations. For example, with leadership of clinical efforts in patient-focused clinical trials from the Multiple Myeloma Research Foundation, International Myeloma Foundation, and MyelomaCrowd. The current proposal includes 3 major research projects. Two of the projects are new, based on research results obtained over the past funding period, while Project 1 is a continuation of efforts to investigate ways of modulating the immune micro-environment to improve the efficacy of oncolytic viral therapy in MM in a phase I clinical trial. Project 2 is an integrated multi-omic analysis of high-risk MM with associated clinical trial highly focused on identifying promising approaches in this group of patients that have not benefited from recent advances. Project 3 is investigating the genetic and microenvironmental mechanisms of progression of smoldering MM to MM to enable early detection of MM requiring treatment. The SPORE also includes Developmental Research and Career Enhancement Programs to pursue novel translational concepts in MM research and new investigators through the programs respectively. Finally, the SPORE will enhance the infrastructure that supports translational MM research through shared core resources in Administration, Biostatistics & Bioinformatics, and Biospecimens & Clinical Database.

项目总结/文摘

项目成果

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.

• DOI: 10.1093/oncolo/oyad053
• 发表时间: 2023-05-08
• 期刊: ONCOLOGIST
• 影响因子: 5.8
• 作者: Fonseca, Rafael;Facon, Thierry;Hashim, Mahmoud;Nair, Sandhya;He, Jianming;Ammann, Eric;Lam, Annette;Wildgust, Mark;Kumar, Shaji
• 通讯作者: Kumar, Shaji

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

• DOI: 10.1038/s41598-016-0021-4
• 发表时间: 2016-12-23
• 期刊: Scientific reports
• 影响因子: 4.6
• 作者: Borad MJ;Egan JB;Condjella RM;Liang WS;Fonseca R;Ritacca NR;McCullough AE;Barrett MT;Hunt KS;Champion MD;Patel MD;Young SW;Silva AC;Ho TH;Halfdanarson TR;McWilliams RR;Lazaridis KN;Ramanathan RK;Baker A;Aldrich J;Kurdoglu A;Izatt T;Christoforides A;Cherni I;Nasser S;Reiman R;Cuyugan L;McDonald J;Adkins J;Mastrian SD;Valdez R;Jaroszewski DE;Von Hoff DD;Craig DW;Stewart AK;Carpten JD;Bryce AH
• 通讯作者: Bryce AH

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

• DOI: 10.1038/bcj.2017.94
• 发表时间: 2017-09-22
• 期刊: Blood cancer journal
• 影响因子: 12.8
• 作者: Miller A;Asmann Y;Cattaneo L;Braggio E;Keats J;Auclair D;Lonial S;MMRF CoMMpass Network;Russell SJ;Stewart AK
• 通讯作者: Stewart AK

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

• DOI: 10.6004/jnccn.2015.0167
• 发表时间: 2015-11
• 期刊: Journal of the National Comprehensive Cancer Network : JNCCN
• 作者: Anderson KC;Alsina M;Atanackovic D;Biermann JS;Chandler JC;Costello C;Djulbegovic B;Fung HC;Gasparetto C;Godby K;Hofmeister C;Holmberg L;Holstein S;Huff CA;Kassim A;Krishnan AY;Kumar SK;Liedtke M;Lunning M;Raje N;Singhal S;Smith C;Somlo G;Stockerl-Goldstein K;Treon SP;Weber D;Yahalom J;Shead DA;Kumar R;National Comprehensive Cancer Network
• 通讯作者: National Comprehensive Cancer Network

Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.

• DOI: 10.1038/s41409-020-0916-3
• 发表时间: 2020-11
• 期刊: Bone marrow transplantation
• 影响因子: 4.8
• 作者: Al Saleh AS;Sidiqi MH;Lee J;Dispenzieri A;Muchtar E;Buadi FK;Warsame R;Lacy MQ;Dingli D;Leung N;Gonsalves WI;Kapoor P;Kourelis TV;Skaer CA;Wittwer SK;Wolf RC;Hogan WJ;Kumar SK;Jacob E;Gertz MA
• 通讯作者: Gertz MA